High-dose melphalan and autologous hematopoietic stem cell transplant in patient with C3 glomerulonephritis associated with monoclonal gammopathy

Nicola Lepori, Wisit Cheungpasitporn, Sanjeev M Sethi, David Murray, Shaji K Kumar, Nelson Leung, Karthik Giridhar, Fernando Custodio Fervenza

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

There is currently no standard treatment for monoclonal immunoglobulin (MIg)-associated C3 glomerulopathy, and treatment is often dictated by the extent of the monoclonal gammopathy. Although chemotherapy treatment for MIg-associated C3 glomerulopathy may stabilize renal function, the overall renal prognosis of MIgassociated C3 glomerulopathy is still poor with frequent progression to end-stage renal disease. We present a case of a 55-year-old man with IgG-? gammopathy-associated C3 glomerulonephritis (C3GN) with bone marrow biopsy demonstrating 5 - 10 ?-restricted plasma cells. Following chemotherapy treatment unfortunately, the patient encountered relapsing courses of the disease. The patient subsequently received high-dose melphalan treatment followed by autologous hematopoietic stem cell transplant (ASCT). At 8 months follow-up, the patient remained hematologic response with stable kidney function. Since ASCT can offer durable hematologic remission, ASCT can potentially be a curative treatment option for patients with MIg-associated C3GN.

Original languageEnglish (US)
Pages (from-to)291-299
Number of pages9
JournalClinical Nephrology
Volume89
Issue number4
DOIs
StatePublished - Apr 1 2018

Fingerprint

Paraproteinemias
Melphalan
Glomerulonephritis
Hematopoietic Stem Cells
Transplants
Immunoglobulins
Kidney
Therapeutics
Drug Therapy
Plasma Cells
Chronic Kidney Failure
Immunoglobulin G
Bone Marrow
Biopsy

Keywords

  • C3 glomerulopathy
  • Complement alternative pathway
  • Membranoproliferative glomerulonephritis
  • Monoclonal gammopathy
  • Stem cell transplant

ASJC Scopus subject areas

  • Nephrology

Cite this

High-dose melphalan and autologous hematopoietic stem cell transplant in patient with C3 glomerulonephritis associated with monoclonal gammopathy. / Lepori, Nicola; Cheungpasitporn, Wisit; Sethi, Sanjeev M; Murray, David; Kumar, Shaji K; Leung, Nelson; Giridhar, Karthik; Fervenza, Fernando Custodio.

In: Clinical Nephrology, Vol. 89, No. 4, 01.04.2018, p. 291-299.

Research output: Contribution to journalArticle

@article{187afe7c24e049cc9b54566c6ea1d769,
title = "High-dose melphalan and autologous hematopoietic stem cell transplant in patient with C3 glomerulonephritis associated with monoclonal gammopathy",
abstract = "There is currently no standard treatment for monoclonal immunoglobulin (MIg)-associated C3 glomerulopathy, and treatment is often dictated by the extent of the monoclonal gammopathy. Although chemotherapy treatment for MIg-associated C3 glomerulopathy may stabilize renal function, the overall renal prognosis of MIgassociated C3 glomerulopathy is still poor with frequent progression to end-stage renal disease. We present a case of a 55-year-old man with IgG-? gammopathy-associated C3 glomerulonephritis (C3GN) with bone marrow biopsy demonstrating 5 - 10 ?-restricted plasma cells. Following chemotherapy treatment unfortunately, the patient encountered relapsing courses of the disease. The patient subsequently received high-dose melphalan treatment followed by autologous hematopoietic stem cell transplant (ASCT). At 8 months follow-up, the patient remained hematologic response with stable kidney function. Since ASCT can offer durable hematologic remission, ASCT can potentially be a curative treatment option for patients with MIg-associated C3GN.",
keywords = "C3 glomerulopathy, Complement alternative pathway, Membranoproliferative glomerulonephritis, Monoclonal gammopathy, Stem cell transplant",
author = "Nicola Lepori and Wisit Cheungpasitporn and Sethi, {Sanjeev M} and David Murray and Kumar, {Shaji K} and Nelson Leung and Karthik Giridhar and Fervenza, {Fernando Custodio}",
year = "2018",
month = "4",
day = "1",
doi = "10.5414/CN109300",
language = "English (US)",
volume = "89",
pages = "291--299",
journal = "Clinical Nephrology",
issn = "0301-0430",
publisher = "Dustri-Verlag Dr. Karl Feistle",
number = "4",

}

TY - JOUR

T1 - High-dose melphalan and autologous hematopoietic stem cell transplant in patient with C3 glomerulonephritis associated with monoclonal gammopathy

AU - Lepori, Nicola

AU - Cheungpasitporn, Wisit

AU - Sethi, Sanjeev M

AU - Murray, David

AU - Kumar, Shaji K

AU - Leung, Nelson

AU - Giridhar, Karthik

AU - Fervenza, Fernando Custodio

PY - 2018/4/1

Y1 - 2018/4/1

N2 - There is currently no standard treatment for monoclonal immunoglobulin (MIg)-associated C3 glomerulopathy, and treatment is often dictated by the extent of the monoclonal gammopathy. Although chemotherapy treatment for MIg-associated C3 glomerulopathy may stabilize renal function, the overall renal prognosis of MIgassociated C3 glomerulopathy is still poor with frequent progression to end-stage renal disease. We present a case of a 55-year-old man with IgG-? gammopathy-associated C3 glomerulonephritis (C3GN) with bone marrow biopsy demonstrating 5 - 10 ?-restricted plasma cells. Following chemotherapy treatment unfortunately, the patient encountered relapsing courses of the disease. The patient subsequently received high-dose melphalan treatment followed by autologous hematopoietic stem cell transplant (ASCT). At 8 months follow-up, the patient remained hematologic response with stable kidney function. Since ASCT can offer durable hematologic remission, ASCT can potentially be a curative treatment option for patients with MIg-associated C3GN.

AB - There is currently no standard treatment for monoclonal immunoglobulin (MIg)-associated C3 glomerulopathy, and treatment is often dictated by the extent of the monoclonal gammopathy. Although chemotherapy treatment for MIg-associated C3 glomerulopathy may stabilize renal function, the overall renal prognosis of MIgassociated C3 glomerulopathy is still poor with frequent progression to end-stage renal disease. We present a case of a 55-year-old man with IgG-? gammopathy-associated C3 glomerulonephritis (C3GN) with bone marrow biopsy demonstrating 5 - 10 ?-restricted plasma cells. Following chemotherapy treatment unfortunately, the patient encountered relapsing courses of the disease. The patient subsequently received high-dose melphalan treatment followed by autologous hematopoietic stem cell transplant (ASCT). At 8 months follow-up, the patient remained hematologic response with stable kidney function. Since ASCT can offer durable hematologic remission, ASCT can potentially be a curative treatment option for patients with MIg-associated C3GN.

KW - C3 glomerulopathy

KW - Complement alternative pathway

KW - Membranoproliferative glomerulonephritis

KW - Monoclonal gammopathy

KW - Stem cell transplant

UR - http://www.scopus.com/inward/record.url?scp=85043378808&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85043378808&partnerID=8YFLogxK

U2 - 10.5414/CN109300

DO - 10.5414/CN109300

M3 - Article

C2 - 29249234

AN - SCOPUS:85043378808

VL - 89

SP - 291

EP - 299

JO - Clinical Nephrology

JF - Clinical Nephrology

SN - 0301-0430

IS - 4

ER -